Form 4: Aileron Therapeutics CEO Acquires Shares Through Indirect Transactions

Aileron Therapeutics' CEO, James Brian Windsor, indirectly acquired shares of common stock through his son on December 5, 2024.

Summary

• James Brian Windsor, the President and CEO of Aileron Therapeutics, indirectly acquired shares of the company's common stock.
• The transactions occurred on December 5, 2024, through purchases made by his son.
• A total of 239 shares were acquired at a price of $2.24 per share, and 161 shares were acquired at $2.25 per share.
• Following these transactions, Mr. Windsor indirectly holds 225 shares through his son, in addition to 7,122 shares held directly.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to insider trading. It does not contain any information that would indicate a positive or negative sentiment.

Management Comments

• The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This is a routine filing related to insider trading activity, which is common for publicly traded companies. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are relatively small in scale compared to typical insider trading activity in larger biotech companies.

Stakeholder Impact

• The indirect purchase of shares by the CEO may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Aileron Therapeutics, James Brian Windsor, insider trading, share acquisition, common stock, SEC Form 4